Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
12 stopped studies mapped to Primary Central Nervous System Lymphoma and descendants · 75% state a reason
Over the 12 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06922604 | Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System… | Phase 1 | suspended | Apr 10, 2025 | City of Hope Medical Center | Pending Amendment Approval | Other (stated, no rule matched) |
| NCT04073147 | Venetoclax and Obinutuzumab for Relapsed/Refractory Primary CNS Lymphoma(VENOBI-CNS) | Phase 1 | terminated | Aug 29, 2019 | Klinikum Stuttgart | low recruitment | Enrollment / accrual |
| NCT01973062 | Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System… | Phase 2 | terminated | Oct 31, 2013 | Case Comprehensive Cancer Center | Funding Unavailable | Funding |
| NCT01251913 | A Pilot Study of Inpatient Hospice With Procurement of Brain Tumor Tissue on Expiration… | — | terminated | Dec 2, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT03120000 | PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System… | Phase 2 | withdrawn | Apr 19, 2017 | PIQUR Therapeutics AG | Withdrawn | Other (stated, no rule matched) |
| NCT03212807 | Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS…(DuRIANS) | Phase 2 | withdrawn | Jul 11, 2017 | Singapore General Hospital | FDA Hold for Combination Studies using Imids and PD1/PDL1 Compounds | Other (stated, no rule matched) |
| NCT00710151 | Neurotoxicity in Primary Central Nervous System Lymphoma (PCNSL): An International… | — | terminated | Jul 4, 2008 | OHSU Knight Cancer Institute | not stated | Not stated |
| NCT01944943 | Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or…(VISMOLY) | Phase 2 | terminated | Sep 18, 2013 | The Lymphoma Academic Research Organisation | lack of efficacy | Efficacy / futility |
| NCT02113007 | Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous… | Phase 2 | terminated | Apr 14, 2014 | SCRI Development Innovations, LLC | Closed early due to slow accrual. | Enrollment / accrual |
| NCT00003505 | Antineoplaston Therapy in Treating Patients With Primary Central Nervous System Lymphoma | Phase 2 | withdrawn | Jan 27, 2003 | Burzynski Research Institute | not stated | Not stated |
| NCT00036855 | Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in… | Phase 1 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00712062 | Study of Pemetrexed to Treat Recurrent or Progressive Primary Central Nervous System… | Phase 2 | withdrawn | Jul 9, 2008 | University of Florida | Lack of accrual | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jul 6, 2026source: clinicaltrials